Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Deoghar, India.
Department of Biochemistry, Bharath Medical College and Hospital (BIHER), Chennai, India.
Gynecol Endocrinol. 2021 Oct;37(10):879-884. doi: 10.1080/09513590.2021.1950136. Epub 2021 Jul 9.
Adropin is a peptide hormone with potential implications in patients with polycystic ovary syndrome (PCOS). The aim of this meta-analysis was to compare the circulating (serum/plasma) and follicular fluid adropin levels between human PCOS patients and non-PCOS controls.
Relevant studies were retrieved by online database and manual searching. The standardized mean differences (SMDs) with 95% confidence intervals (CIs) were obtained by a random-effects meta-analysis. Meta-analysis of correlations was performed for the associations of adropin with anthropometric, lipid, insulin resistance and hormonal covariates. The funnel plot analysis with Begg's and Egger's tests was used for publication bias.
A total of 9 studies were included in this meta-analysis. The results indicated that the adropin levels were significantly decreased in PCOS patients as compared to non-PCOS controls (SMD = -1.87, 95% CI = -2.55 to -1.18, < .0001). This decrease was more evident in overweight PCOS patients than their normoweight counterparts (SMD = -0.55, 95% CI = -0.80 to -0.30, < .0001). A one-study leave-out sensitivity analysis indicated that no single study had a significant influence on the overall outcome, suggesting the robustness of this meta-analysis. There were significant associations of decreased adropin levels with the body mass index, dyslipidemia and insulin resistance in PCOS.
Adropin levels are significantly reduced in PCOS patients compared to controls, and this decrease was more evident in overweight PCOS patients.
阿多品是一种具有潜在意义的肽激素，在多囊卵巢综合征（PCOS）患者中。本荟萃分析的目的是比较多囊卵巢综合征患者和非多囊卵巢综合征对照组之间循环（血清/血浆）和卵泡液阿多品水平。
通过在线数据库和手动搜索检索相关研究。采用随机效应荟萃分析获得标准化均数差（SMD）及其 95%置信区间（CI）。进行荟萃分析以评估阿多品与人体测量学、脂质、胰岛素抵抗和激素协变量的相关性。采用漏斗图分析贝格检验和埃格检验进行发表偏倚分析。
本荟萃分析共纳入 9 项研究。结果表明，与非多囊卵巢综合征对照组相比，多囊卵巢综合征患者的阿多品水平显著降低（SMD = -1.87，95%CI = -2.55 至 -1.18，<0.0001）。超重多囊卵巢综合征患者的降幅比正常体重患者更为明显（SMD = -0.55，95%CI = -0.80 至 -0.30，<0.0001）。一项剔除单研究的敏感性分析表明，没有单个研究对总体结果有显著影响，表明本荟萃分析的稳健性。多囊卵巢综合征患者阿多品水平降低与体重指数、血脂异常和胰岛素抵抗存在显著相关性。
与对照组相比，多囊卵巢综合征患者的阿多品水平显著降低，超重多囊卵巢综合征患者的降幅更为明显。
